LPTX Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 272.52%, SMA50 325.67%, SMA200 409.57%). The stock’s 14-day RSI is 89.47 (overbought), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -43.21% below its high and over 822.18% above its low.

Leap Therapeutics, Inc. generated EPS of -$1.59 over the past year. Five-year average earnings growth is 34.28%. The latest quarter delivered EPS of $0.92. The next quarter is forecast at $nan. Next year's EPS is expected at $38.94. Leap Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended March 16, 2026, missed forecasts by -560.0%. The prior quarter beat by -66.79%. Over the last six quarters, Apple has recorded several small beats. These include -4.35% in November 13, 2024.

Leap Therapeutics, Inc. has 41.44 million shares outstanding. The public float is 32.22 million shares, elevated short interest at 4.33% of float. This equals 1.53 million shares. The short ratio is 3.97 days. Institutional investors hold 26.33% of the float. Insiders own 16.2%. BeiGene, Ltd. holds 7.35 million shares, PERCEPTIVE ADVISORS LLC has 3.51 million shares and ONSI DOUGLAS E has 592.80 thousand shares.

Leap Therapeutics, Inc. (NASDAQ:LPTX) closed at $0.77 USD, losing -$0.03 (-3.15%) from the previous close of $0.79. The stock is currently mid-range between its 52-week high and low $0.22 and $3.58. With a market capitalization of about $31.86 million, Leap Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.09). Key stats such as the average daily volume over the past year has been around 26.09 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Leap Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Douglas E. Onsi, the company employs approximately 52 people and listed since January 25, 2017. Leap Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing treatments for various cancers.

Leap Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.20. This means the shares are trading above this model’s fair value.

Leap Therapeutics, Inc. trades at a P/E ratio of 1.2, slightly below the S&P 500 average, with a price-to-sales ratio of 152.42 and a price-to-book ratio of 0.97 suggesting the stock is closer to book value. The P/FCF stands at -0.5, also above market averages.

Leap Therapeutics, Inc. (NASDAQ:LPTX) shares are down -84.09% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Leap Therapeutics, Inc. trading at a premium to the broader market with a P/E of 1.2. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.60, suggesting 861.96% upside. Our AI forecast model points to short-term weakness (-8.18% over two weeks), a medium-term rise (249.8% over three months), and a longer-term gain (882.36% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Leap Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.18%, with price expected at $0.63 by March 31, 2026, within a range of $0.57 to $0.69 3-Month Outlook: Projected rise of 249.8%, reaching $2.40 by June 15, 2026, with a range of $2.29 to $2.52. 1-Year Outlook: Projected gain of 882.36%, with price at $6.74 by March 17, 2027, within a range of $0.00 to $9.57.